不同剂量低分子肝素钙治疗慢性阻塞性肺疾病急性加重期呼吸衰竭的疗效及对血液黏度的影响  

Effects of different doses of low molecular weight heparin calcium on respiratory failure and blood viscosity in patients with acute exacerbation of COPD

作　　者：李剑 LI Jian(Department of Pharmacy,Panjin Central Hospital,Panjin,Liaoning,124010,China)

机构地区：[1]盘锦市中心医院科室药事部,辽宁盘锦124010

出　　处：《当代医学》2023年第8期137-140,共4页Contemporary Medicine

摘　　要：目的探讨慢性阻塞性肺疾病(COPD)急性加重期呼吸衰竭患者采用低分子肝素钙治疗的最佳剂量。方法选取2019年8月至2020年8月于本院就诊的COPD急性加重期呼吸衰竭患者100例作为研究对象,按照随机数字表法分为A组(n=34)、B组(n=33)与C组(n=33),分别给予小剂量、中剂量和大剂量低分子肝素钙治疗。比较3组临床疗效、血液黏度和不良反应。结果3组治疗总有效率比较差异有统计学意义(P<0.05);B组和C组治疗总有效率高于A组,差异有统计学意义(P<0.05);B组和C组治疗总有效率比较差异无统计学意义。治疗后,B组与C组全血低切黏度、全血高切黏度、血浆黏度低于A组(P<0.05),B组与C组比较差异无统计学意义。B组不良反应发生率低于A组、C组,差异有统计学意义(P<0.05)。结论中剂量低分子肝素钙治疗COPD急性加重期呼吸衰竭患者效果显著,能降低血液黏度,安全性较高,值得临床推广应用。Objective To explore the different dose of low molecular weight heparin calcium for the treatment of respiratory failure in patients with acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods A total of 100 patients with acute exacerbation of COPD with respiratory failure who were hospitalized in our hospital from August 2019 to August 2020 were selected as the study subjects,and they were divided into group A(n=34),group B(n=33),and group C(n=33)using random number table method,three groups were treated with low,medium,and large doses of low molecular weight heparin calcium,respectively.The clinical efficacy,blood viscosity,and adverse reactions were compared among the three groups.Results There was significant difference in the total effective rate among the three groups(P<0.05).The total effective rate of group B and group C was higher than that of group A,and the difference was statistically significant(P<0.05).There was no significant difference in the total effective rate between group B and group C.After treatment,whole blood low tangential viscosity,whole blood high tangential viscosity and plasma viscosity of group B and group C were lower than those of group A,the differences were statistically significant(P<0.05),but there was no statistically significant difference between group B and group C.The incidence of adverse reactions in group B was lower than that in group A and group C,and the difference was statistically significant(P<0.05).Conclusion Medium dose low molecular weight heparin calcium is effective in treating patients with acute exacerbation of COPD with respiratory failure,can reduce blood viscosity,and has high safety,which is worthy of clinical promotion and application.

关 键 词：慢性阻塞性肺疾病 呼吸衰竭 低分子肝素钙 临床疗效 血液黏度 不良反应 

分 类 号：R576[医药卫生—消化系统]